UNICYCIVE THERAPEUTICS, INC. Increase (Decrease) in Deferred Revenue
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Increase (Decrease) in Deferred Revenue of $146.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2022-08-15
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2021-12-31 was -$103.00K, a 235.53% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2021-09-30 was $92.00K, a 58.62% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2021-06-30 was $120.00K.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2021-03-31 was $37.00K.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2021 was $146.00K, a 63.13% decline from fiscal 2020.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2020 was $396.00K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$103.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$11.00K derived: sum of 2 quarters · filed 2022-03-31 | $109.00K derived: sum of 3 quarters · filed 2022-08-15 | $146.00K 10-K · filed 2022-03-31 |
| 2021-09-30 | $92.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $212.00K derived: sum of 2 quarters · filed 2022-08-15 | $249.00K 10-Q · filed 2021-11-12 | $325.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-06-30 | $120.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $157.00K 10-Q · filed 2022-08-15 | $233.00K derived: sum of 3 quarters · filed 2022-08-15 | $291.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $37.00K 10-Q · filed 2022-05-12 | $113.00K derived: sum of 2 quarters · filed 2022-05-12 | $171.00K derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $134.00K derived: sum of 2 quarters · filed 2022-03-31 | $396.00K 10-K · filed 2022-03-31 | |
| 2020-09-30 | $58.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $320.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $262.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |